JP Patent

JP7093764B2 — 骨髄異形成症候群の治療方法

Assigned to Celgene Corp · Expires 2022-06-30 · 4y expired

What this patent protects

Patent listed against enasidenib-mesylate.

Drugs covered by this patent

enasidenib-mesylate (ENASIDENIB MESYLATE)

Patent Metadata

Patent number: JP7093764B2
Jurisdiction: JP
Classification: —
Expires: 2022-06-30
Drug substance claim: No
Drug product claim: No
Assignee: Celgene Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.